900 % in 4 Handelstagen von 0,50 auf 6 Dollar. Scharfe Korrektur bis zum 63,2 Retracement etwa auf 2,47.
News heute vorbörslich und Verbörse feiert schon mal wieder. Prima BioMed Announces New IP for Its Lead IMP321 Development Program By Market Wire, May 29, 2015, 07:00:00 AM EDT Vote up AAA
SYDNEY, AUSTRALIA -- (Marketwired) -- 05/29/15 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) ("Prima" or the "Company"), a leading immuno-oncology company, today announced that it has made substantial progress with its lead product, IMP321.
Prima advises that it has filed for patent protection over the use of IMP321 in conjunction with checkpoint inhibitor molecules, which the company believes gives IMP321 significant clinical and commercial advantages. Prima's CEO, Marc Voigt, and CSO & CMO, Professor Frédéric Triebel, will be attending the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago to discuss IMP321 with key opinion leaders in the immuno-oncology field.
|